

Dwight H Owen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5553365/publications.pdf>

Version: 2024-02-01

82
papers

2,255
citations

331670

21
h-index

254184

43
g-index

84
all docs

84
docs citations

84
times ranked

3231
citing authors

#	ARTICLE	IF	CITATIONS
1	Targeting RET in Patients With <i>RET</i> -Rearranged Lung Cancers: Results From the Global, Multicenter <i>RET</i> Registry. <i>Journal of Clinical Oncology</i> , 2017, 35, 1403-1410.	1.6	277
2	Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2020, 6, 1952.	7.1	241
3	Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated Colitis. <i>Journal of Clinical Oncology</i> , 2019, 37, 2738-2745.	1.6	138
4	Frequency of Brain Metastases and Multikinase Inhibitor Outcomes in Patients With <i>RET</i> -Rearranged Lung Cancers. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1595-1601.	1.1	137
5	Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease. <i>Journal of Clinical Oncology</i> , 2020, 38, 576-583.	1.6	135
6	DLL3: an emerging target in small cell lung cancer. <i>Journal of Hematology and Oncology</i> , 2019, 12, 61.	17.0	115
7	Acute kidney injury in patients treated with immune checkpoint inhibitors. , 2021, 9, e003467.		103
8	Incidence, Risk Factors, and Effect on Survival of Immune-related Adverse Events in Patients With Non-Small-cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2018, 19, e893-e900.	2.6	98
9	Change in neutrophil to lymphocyte ratio during immunotherapy treatment is a non-linear predictor of patient outcomes in advanced cancers. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 2541-2546.	2.5	93
10	Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors Among Patients Aged 80 Years or Older With Cancer. <i>JAMA Oncology</i> , 2021, 7, 1856.	7.1	74
11	Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 1177-1187.	4.2	66
12	Intracranial Efficacy of Selpercatinib in <i>RET</i> Fusion-Positive Non-Small Cell Lung Cancers on the LIBRETTO-001 Trial. <i>Clinical Cancer Research</i> , 2021, 27, 4160-4167.	7.0	64
13	Immunotherapy in surgically resectable non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2018, 10, S404-S411.	1.4	53
14	Expression Patterns, Prognostic Value, and Intratumoral Heterogeneity of PD-L1 and PD-1 in Thymoma and Thymic Carcinoma. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1204-1212.	1.1	46
15	Second cancer incidence in CLL patients receiving BTK inhibitors. <i>Leukemia</i> , 2020, 34, 3197-3205.	7.2	45
16	Inferring the role of the microbiome on survival in patients treated with immune checkpoint inhibitors: causal modeling, timing, and classes of concomitant medications. <i>BMC Cancer</i> , 2020, 20, 383.	2.6	45
17	Frequency, Morbidity, and Mortality of Bone Metastases in Advanced Hepatocellular Carcinoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 50-58.	4.9	41
18	ASSOCIATION OF TRANSFORMING GROWTH FACTOR- β 1 GENE POLYMORPHISM WITH REFLUX NEPHROPATHY. <i>Journal of Urology</i> , 2005, 174, 1609-1611.	0.4	40

#	ARTICLE	IF	CITATIONS
19	Combination therapy with capecitabine and temozolomide in patients with low and high grade neuroendocrine tumors, with an exploratory analysis of O6-methylguanine DNA methyltransferase as a biomarker for response. <i>Oncotarget</i> , 2017, 8, 104046-104056.	1.8	35
20	Association between immune-related adverse event timing and treatment outcomes. <i>OncoImmunology</i> , 2022, 11, 2017162.	4.6	33
21	KRAS G12V Mutation in Acquired Resistance to Combined BRAF and MEK Inhibition in Papillary Thyroid Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 409-413.	4.9	30
22	Bone Metastases, Skeletal-Related Events, and Survival in Patients With Metastatic Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 915-921.	4.9	27
23	Targeting Tumor-Associated Macrophages in Cancer Immunotherapy. <i>Cancers</i> , 2021, 13, 5318.	3.7	26
24	Targeting BRAF Mutations in High-Grade Neuroendocrine Carcinoma of the Colon. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 1035-1040.	4.9	24
25	Checkpoint inhibitor immunotherapy toxicity and overall survival among older adults with advanced cancer. <i>Journal of Geriatric Oncology</i> , 2021, 12, 813-819.	1.0	23
26	The Role of Malnutrition and Muscle Wasting in Advanced Lung Cancer. <i>Current Oncology Reports</i> , 2020, 22, 54.	4.0	20
27	Metastatic Adrenocortical Carcinoma: a Single Institutional Experience. <i>Hormones and Cancer</i> , 2019, 10, 161-167.	4.9	13
28	Programmed cell death-1 (PD-1) and programmed death-ligand 1 (PD-L1) expression in PD-1 inhibitor-associated colitis and its mimics. <i>Histopathology</i> , 2020, 77, 240-249.	2.9	13
29	Serum Albumin: Early Prognostic Marker of Benefit for Immune Checkpoint Inhibitor Monotherapy But Not Chemoimmunotherapy. <i>Clinical Lung Cancer</i> , 2022, 23, 345-355.	2.6	13
30	Impact of immune-related adverse events (irAE) on overall survival (OS) in patients treated with immunotherapy for non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 9080-9080.	1.6	12
31	Immune checkpoint inhibitor-related thrombocytopenia: incidence, risk factors and effect on survival. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 1157-1165.	4.2	12
32	Multicenter phase 2 trial of nintedanib in advanced nonpancreatic neuroendocrine tumors. <i>Cancer</i> , 2020, 126, 3689-3697.	4.1	11
33	Brief report: inhaled corticosteroid use and the risk of checkpoint inhibitor pneumonitis in patients with advanced cancer. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 2403-2408.	4.2	10
34	Homologous recombination and DNA repair mutations in patients treated with carboplatin and nab-paclitaxel for metastatic non-small cell lung cancer. <i>Lung Cancer</i> , 2019, 134, 167-173.	2.0	9
35	CLO20-054: A Phase 2 Trial of Nivolumab and Temozolomide in Advanced Neuroendocrine Tumors (NETs): Interim Efficacy Analysis. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, CLO20-054.	4.9	9
36	Targeting RET in patients with RET-rearranged lung cancers: Results from a global registry.. <i>Journal of Clinical Oncology</i> , 2016, 34, 9014-9014.	1.6	8

#	ARTICLE	IF	CITATIONS
37	P2.04-88 Surgical Outcomes of a Multicenter Phase II Trial of Neoadjuvant Atezolizumab in Resectable Stages IB-IIIb NSCLC: Update on LCMC3 Clinical Trial. <i>Journal of Thoracic Oncology</i> , 2019, 14, S744.	1.1	7
38	Minimally Invasive Lobectomy for Residual Primary Tumors of Advanced Non-Small-Cell Lung Cancer After Treatment With Immune Checkpoint Inhibitors: Case Series and Clinical Considerations. <i>Clinical Lung Cancer</i> , 2020, 21, e265-e269.	2.6	7
39	Comparative assessment of manual chart review and ICD claims data in evaluating immunotherapy-related adverse events. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 2761-2769.	4.2	7
40	Treatment of Non-Small-Cell Lung Cancer Based on Circulating Cell-Free DNA and Impact of Variation Allele Frequency. <i>Clinical Lung Cancer</i> , 2021, 22, e519-e527.	2.6	7
41	OA13.07 Neoadjuvant Atezolizumab in Resectable NSCLC Patients: Immunophenotyping Results from the Interim Analysis of the Multicenter Trial LCMC3. <i>Journal of Thoracic Oncology</i> , 2019, 14, S242-S243.	1.1	6
42	Deep and Durable Response to Nivolumab and Temozolomide in Small-Cell Lung Cancer Associated With an Early Decrease in Myeloid-Derived Suppressor Cells. <i>Clinical Lung Cancer</i> , 2021, 22, e487-e497.	2.6	6
43	Murine cancer cachexia models replicate elevated catabolic pembrolizumab clearance in humans. <i>JCSM Rapid Communications</i> , 2021, 4, 232-244.	1.6	6
44	Risk factors and predictors of immune-related adverse events: implications for patients with non-small cell lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 861-874.	2.4	6
45	Association Between RBC Antigen Allo-Antibodies and Immune-Related Adverse Events During Immune Checkpoint Inhibitor Treatment for Advanced Cancers. <i>Cancer Management and Research</i> , 2020, Volume 12, 11743-11749.	1.9	5
46	Multicenter phase 2 study of nintedanib in patients (pts) with advanced progressing carcinoid tumors. <i>Journal of Clinical Oncology</i> , 2018, 36, 4105-4105.	1.6	5
47	Immune-Related Adverse Events (irAEs): Implications for Immune Checkpoint Inhibitor Therapy. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 1287-1290.	4.9	5
48	Favorable and Durable Response to Pazopanib in Metastatic Refractory Paraganglioma. <i>Journal of Oncology Practice</i> , 2017, 13, 840-842.	2.5	4
49	Immune related adverse events across cancer types: Incidence, risk factors and survival. <i>Annals of Oncology</i> , 2018, 29, viii630-viii631.	1.2	4
50	Biomarkers for Immunotherapy. <i>Thoracic Surgery Clinics</i> , 2020, 30, 207-214.	1.0	4
51	Response to the Selective RET Inhibitor Selpercatinib (LOXO-292) in a Patient With RET Fusion-positive Atypical Lung Carcinoid. <i>Clinical Lung Cancer</i> , 2021, 22, e442-e445.	2.6	4
52	Effect of concomitant medications on overall survival in patients with cancer undergoing immunotherapy. <i>Journal of Clinical Oncology</i> , 2019, 37, 94-94.	1.6	4
53	Do toxicity patterns vary between programmed death-1 and programmed death ligand-1 inhibitors?. <i>Journal of Thoracic Disease</i> , 2018, 10, S4069-S4072.	1.4	3
54	MA11.11 STK11/LKB1 Genomic Alterations Are Associated with Inferior Clinical Outcomes with Chemo-Immunotherapy in Non-Squamous NSCLC. <i>Journal of Thoracic Oncology</i> , 2019, 14, S294-S295.	1.1	3

#	ARTICLE	IF	CITATIONS
55	Neuroendocrine and Rare Tumor Advances: A New and Promising TRAIL Emerges. <i>Clinical Cancer Research</i> , 2022, 28, 1748-1750.	7.0	3
56	P2.04-020 Expression Patterns and Prognostic Value of PD-L1 and PD-1 in Thymoma and Thymic Carcinoma. <i>Journal of Thoracic Oncology</i> , 2017, 12, S1008-S1009.	1.1	2
57	Clinical Course of Hypertrophic Pulmonary Osteoarthropathy in a Patient Receiving Immune Checkpoint Inhibitor Therapy. <i>Clinical Lung Cancer</i> , 2020, 21, e243-e245.	2.6	2
58	A phase II study of atezolizumab as neoadjuvant and adjuvant therapy in patients (pts) with resectable non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS8580-TPS8580.	1.6	2
59	Immune-mediated colitis after resumption of immune checkpoint inhibitor therapy.. <i>Journal of Clinical Oncology</i> , 2019, 37, 2577-2577.	1.6	2
60	MA16.03 Global RET Registry (GLORY): Activity of RET-Directed Targeted Therapies in RET-Rearranged Lung Cancers. <i>Journal of Thoracic Oncology</i> , 2017, 12, S435-S436.	1.1	1
61	End of life resource utilization among patients receiving immunotherapy for advanced cancer. <i>Annals of Oncology</i> , 2018, 29, viii553.	1.2	1
62	MA04.10 Comprehensive Peripheral Blood Immunophenotyping and T-Cell Clonal Analysis During Neoadjuvant Immunotherapy with Atezolizumab in NSCLC. <i>Journal of Thoracic Oncology</i> , 2018, 13, S369.	1.1	1
63	P1.01-71 Bone Metastases and Skeletal-Related Events in Patients with Metastatic NSCLC Treated with ICIs: A Multi-Institutional Study. <i>Journal of Thoracic Oncology</i> , 2019, 14, S387.	1.1	1
64	775â€ŒImmune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease. <i>American Journal of Gastroenterology</i> , 2019, 114, S450-S451.	0.4	1
65	Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort. , 2020, 69, 1177.		1
66	Hepatocellular carcinoma (HCC) and bone metastases (Mets).. <i>Journal of Clinical Oncology</i> , 2015, 33, e15129-e15129.	1.6	1
67	Is immunotherapy toxicity associated with improved overall survival among older adults with advanced cancer?. <i>Journal of Clinical Oncology</i> , 2019, 37, 6580-6580.	1.6	1
68	Immune pneumonitis-related treatment discontinuations and outcomes in metastatic non-small cell lung cancer treated with nivolumab: A pooled analysis from a multi-institutional international collaboration.. <i>Journal of Clinical Oncology</i> , 2019, 37, 118-118.	1.6	1
69	An Early Lesson. <i>Journal of Palliative Medicine</i> , 2015, 18, 86-86.	1.1	0
70	P2.06-019 A Phase II Study of Atezolizumab as Neoadjuvant and Adjuvant Therapy in Patients (pts) with Resectable Non-Small Cell Lung Cancer (NSCLC). <i>Journal of Thoracic Oncology</i> , 2017, 12, S1082.	1.1	0
71	Systemic Therapy for Advanced Metastatic Thyroid Cancer. , 2017, , 433-450.		0
72	New treatment options and challenges for patients with anaplastic lymphoma kinase-positive non-small cell lung cancer with brain metastases. <i>Journal of Thoracic Disease</i> , 2017, 9, E158-E161.	1.4	0

#	ARTICLE	IF	CITATIONS
73	Reply to J. Delyon et al. Journal of Clinical Oncology, 2019, 37, 3564-3565.	1.6	0
74	SECOND CANCER INCIDENCE IN CLL PATIENTS RECEIVING BTK INHIBITORS. Hematological Oncology, 2019, 37, 382-383.	1.7	0
75	Emerging biomarkers for checkpoint inhibitors in thymic epithelial tumors. Mediastinum, 2019, 3, 3-3.	1.1	0
76	EP1.12-38 Retrospective Analysis of Immunotherapy Utilization in Advanced Small Cell Carcinoma at an Academic Cancer Center. Journal of Thoracic Oncology, 2019, 14, S1030.	1.1	0
77	Abstract 3116: MGMT immunohistochemistry (IHC) as a biomarker for response to combination therapy with capecitabine and temozolomide (C/T) in patients (pts) with advanced neuroendocrine carcinomas (aNEC). , 2016, , .		0
78	Outcomes of metastatic adrenocortical carcinoma (ACC): A 16-year single institutional experience.. Journal of Clinical Oncology, 2017, 35, e16088-e16088.	1.6	0
79	Recurrent and de-novo autoimmune hemolytic anemia in patients treated with immunotherapy for advanced cancer.. Journal of Clinical Oncology, 2019, 37, e14170-e14170.	1.6	0
80	Re-evaluating the neutrophil-to-lymphocyte ratio: Machine learning-based variable selection for predicting survival at twelve months in late-stage cancer patients receiving immunotherapy.. Journal of Clinical Oncology, 2019, 37, e18201-e18201.	1.6	0
81	Abstract 4394: Utilizing pharmacokinetics and toxicity data in the translational drug interaction knowledgebase to bridge the phase I cancer drug combination studies. , 2020, , .		0
82	Harmonized Outcome Measures for Use in Non-“Small Cell Lung Cancer Patient Registries and Clinical Practice. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, , .	4.9	0